Active Ingredient History
Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Zolpidem interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem in vitro binds the BZ1 receptor preferentially with a high affinity ratio of the α1/α5 subunits. This selective binding of zolpidem on the BZ1 receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep in human studies of zolpidem tartrate at hypnotic doses. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Sleep Initiation and Maintenance Disorders (approved 1992)
Abdominoplasty (Phase 4)
Acute Coronary Syndrome (Phase 4)
Aging (Phase 4)
Anemia, Iron-Deficiency (Phase 3)
Anxiety Disorders (Phase 3)
Arthritis (Phase 1)
Arthroplasty (Phase 1)
Autism Spectrum Disorder (Phase 2)
Autistic Disorder (Phase 2)
Back Pain (Phase 1/Phase 2)
Burns (Phase 2)
Cognition (Phase 4)
Consciousness Disorders (Phase 2)
Delirium (Phase 4)
Dementia (Phase 3)
Depression (Phase 4)
Dystonic Disorders (Early Phase 1)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 4)
Hip Fractures (Phase 4)
Marijuana Abuse (Phase 1)
Memory (Phase 4)
Obesity (Phase 1)
Parkinson Disease (Phase 2)
Performance-Enhancing Substances (Early Phase 1)
Pharmacokinetics (Early Phase 1)
Pharmacologic Actions (Phase 4)
Postoperative Complications (Phase 1)
Posture (Phase 4)
Prostatic Neoplasms (Phase 1)
Psychomotor Disorders (Phase 4)
Psychophysiologic Disorders (Phase 3)
Schizophrenia (Phase 3)
Sleep (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sleep Apnea Syndromes (Phase 4)
Sleep Deprivation (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Sleep Wake Disorders (Phase 4)
Substance Abuse, Oral (Phase 1)
Substance-Related Disorders (Phase 2/Phase 3)
Suicidal Ideation (Phase 4)
Therapeutic Equivalency (Phase 1)
Therapeutics (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
